Kevin C. Conlon, M.D.
Kevin C. Conlon, M.D.
Staff Clinician

Center for Cancer Research
National Cancer Institute

Building 10 - Magnuson Clinical Center, Room 5A-22
Bethesda, MD 20892
301-496-7417

Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.

Areas of Expertise
immunotherapy, IL-15
Link to Clinicaltrials.gov Protocol ID Referral Phone

KW 0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCI-13-C-0069 301-496-0499

Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)

NCI-13-C-0006 301-496-0499

A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers

NCI-12-C-0113 301-496-0499

A Phase 1 Study of Subcutaneous Recombinant Human hetIL-15 (IL15 / sIL-15Ra) in Adults with Metastatic Cancers

NCI-15-C-0110 301-496-0499
Selected Publications
  1. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.
    Blood. 121: 2029-37, 2013. [ Journal Article ]
  2. Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
    Blood. 121: 476-84, 2013. [ Journal Article ]
  3. Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM.
    J. Immunother.. 35: 629-40, 2012. [ Journal Article ]
  4. Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.
    Blood. 120: 1816-9, 2012. [ Journal Article ]

Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.

Name Position
Nancy Beltran Patient Care Coordinator (Contr.)
Erin Corcoran Data Manager (Contr.)
Tatyana Worthy R.N. Nurse Specialist

Summary

Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.

Areas of Expertise
immunotherapy, IL-15

Clinical Trials

Link to Clinicaltrials.gov Protocol ID Referral Phone

KW 0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCI-13-C-0069 301-496-0499

Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)

NCI-13-C-0006 301-496-0499

A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers

NCI-12-C-0113 301-496-0499

A Phase 1 Study of Subcutaneous Recombinant Human hetIL-15 (IL15 / sIL-15Ra) in Adults with Metastatic Cancers

NCI-15-C-0110 301-496-0499

Publications

Selected Publications
  1. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.
    Blood. 121: 2029-37, 2013. [ Journal Article ]
  2. Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
    Blood. 121: 476-84, 2013. [ Journal Article ]
  3. Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM.
    J. Immunother.. 35: 629-40, 2012. [ Journal Article ]
  4. Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.
    Blood. 120: 1816-9, 2012. [ Journal Article ]

Biography

Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.

Team

Name Position
Nancy Beltran Patient Care Coordinator (Contr.)
Erin Corcoran Data Manager (Contr.)
Tatyana Worthy R.N. Nurse Specialist